Targeting B2-Receptors to Develop Obesity Therapeutics That Preserve Muscle Mass

• Stimulating the B2 adrenergic receptor to combat obesity
• Leveraging Atrogi’s GPCR discovery platform to discovery precise targets to manage metabolism
• Highlighting ATR-339 clinical data to demonstrate durable, muscle maintaining therapeutics

Speakers:

Paul Little

Chief Executive Officer

Atrogi